References
- Cohen L F, Balow J E, Magrath I T, Poplack D G, Ziegler J L. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68: 486–491
- Flombaum C D. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27: 322–334
- Arrambide K, Toto R D. Tumor lysis syndrome. Semin Nephrol 1993; 13: 273–280
- Conger J D, Falk S A, Guggenheim S J, Burke T J. A micropuncture study of the early phase of acute urate nephropathy. J Clin Invest 1976; 58: 681–689
- Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38(Suppl 10)4–8
- Chasty R C, Liu-Yin J A. Acute tumour lysis syndrome. Br J Hosp Med 1993; 49: 488–492
- Seftel M D, Bruyere H, Copland M, Hogge D E, Horsman D E, Nantel S E, et al. Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22). Eur J Haematol 2002; 69: 193–199
- Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003; 44: 77–83
- Razis E, Arlin Z A, Ahmed T, Feldman E J, Puccio C, Cook P, et al. Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol 1994; 91: 171–174
- Lotfi M, Brandwein J M. Spontaneous acute tumor lysis syndrome in acute myeloid leukemia? A single case report with discussion of the literature. Leuk Lymphoma 1998; 29: 625–628
- Anderson S, Files J. Tumor lysis syndrome secondary to Gemtuzumab Ozogamicin in a patient with acute myelogenous leukemia. J Miss State Med Assoc 2002; 43: 105–106
- Kikuchi T, Miyata A, Fujii S, Kikuchi T. Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy. Rinsho Ketsueki 2003; 44: 1113–1116
- Seki J T, Al-Omar H M, Amato D, Sutton D M. Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. Ann Pharmacother 2003; 37: 675–678
- Hanley J A, McNeil B J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36
- DeLong E R, DeLong D M, Clarke-Pearson D L. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1998; 44: 837–845
- Harrell F E, Lee K L, Mark D B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361–387
- Jekel J F, Elmore J G, Katz D L. Epidemiology, Biostatisitcs, and Preventive Medicine. WB Saunders, Philadelphia, PA 1996
- Al-Bahar S, Pandita R, Dhabhar B N, Al-Bahar E. Acute tumor lysis syndrome in acute lymphoblastic leukemia and Burkitt's lymphoma: experience in a single centre in Kuwait. Ann Oncol 1994; 5: 379
- Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82: 160–165
- Cairo M S, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3–11
- Justice A C, Covinsky K E, Berlin J A. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515–512
- Fang J, Alderman M H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404–2410
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
- Efron B, Tibshirani R J. An Introduction to the Bootstrap. CRC Press, London 1994